deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT02007187

Danhong Injection in the Treatment of Unstable Angina Pectoris

A Randomized, Double-blind, Multicenter, Parallel Controlled Clinical Trial of Danhong Injection in the Treatment of Unstable Angina Pectoris

Sponsor: China Academy of Chinese Medical Sciences

Conditions Unstable Angina Pectoris
Interventions Danhong injection Placebo Standard medical care
Updated 7 times since 2017 Last updated: Nov 29, 2017 Started: Dec 31, 2013 Primary completion: Aug 31, 2017 Completion: Nov 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Unstable Angina Pectoris, this trial is completed. The trial is conducted by China Academy of Chinese Medical Sciences and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Dec 2017 · 11 months · monthly snapshotRecruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Dec 2017 — Jun 2018 [monthly]

    Completed PHASE4

    Status: Recruiting → Completed

  2. Jan 2017 — Dec 2017 [monthly]

    Recruiting PHASE4

    First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • China Academy of Chinese Medical Sciences
  • China Food and Drug Administration
Data source: China Academy of Chinese Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations